Iovance Biotherapeutics
Emilie Amorim is an experienced finance professional who currently serves as the Vice President of Global FP&A at Iovance Biotherapeutics, Inc. Prior to this role, Emilie held various finance positions at prominent companies such as Johnson & Johnson Innovation JJDC Inc, The Janssen Pharmaceutical Companies of Johnson & Johnson, Actelion, VariLite, and Input. Emilie holds a Master of Business Administration (M.B.A.) from the University of San Francisco and a Bachelor's degree in Accounting and Business/Management from IEMI.
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.